Cargando…
Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
Alpelisib, a phosphatidylinositol-3-kinase (PI3K) inhibitor, is a new drug approved for metastatic breast cancer. Hyperglycemia is a known side effect of this medication, however diabetic ketoacidosis is rarely described. We are presenting a 64-year-old female with a known case of Type 2 diabetes me...
Autores principales: | Abufaied, Mohamad, Jumbo, Unwam, Alqalalwah, Adala, Hamad, Mohammad Khair |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663995/ https://www.ncbi.nlm.nih.gov/pubmed/34909343 http://dx.doi.org/10.7759/cureus.19441 |
Ejemplares similares
-
Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
por: Al Zeyoudi, Jawaher, et al.
Publicado: (2021) -
Alpelisib-Induced Diabetic Ketoacidosis
por: Nguyen, Paul, et al.
Publicado: (2021) -
Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient
por: Fugere, Tyler, et al.
Publicado: (2021) -
Alpelisib-Induced Diabetic Ketoacidosis
por: Espinosa, Luis Borges, et al.
Publicado: (2021) -
Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021)